Effect of Curcumin on Lung Inflammation
Status
Conditions
Treatments
Details and patient eligibility
About
Chronic obstructive pulmonary disease (COPD) and lung cancer are leading causes of death and health care use. Diffuse airways inflammation is seen in COPD and is thought to be the reason for deterioration of lung function in COPD. Currently there is no medication available that can modify or reduce this inflammation. Furthermore, from literature review it has been shown that chronic inflammation can result in cancerous changes.
Curcumin is a food additive used for centuries. Several studies showed that curcumin suppress the different inflammatory pathways. Specially, the TNF-alpha and the NF kappa-b are down regulated by this substance. This study was designed to evaluate effect of combination of curcumin+Bioprine on sputum cytology in patients with COPD. This is double-blind randomized pilot study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age equal or more than 45 with moderate COPD: FEV1/FVC ratio less than 70 percent; post bronchodilator FEV1 less than 50 percent
- 20 pack year cigarette smoking
- Stable clinical course (symptoms/ medications) for 8 weeks
- Fixed address/Not planning to leave
- Being able to perform spirometry
- Able to understand and consent
Exclusion criteria
- Other chronic respiratory diseases such as asthma, interstitial fibrosis, sarcoidosis
- Heart failure NYH III & IV; symptomatic liver or renal failure
- Dementia or other neurocognitive deficit preventing completion of symptom diary
- Use of inhaled or systemic corticosteroids within 8 weeks of enrollment in the study
Trial design
Primary purpose
Allocation
Interventional model
Masking
57 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal